SAMe 200 mg

SAMe 200 mg

NOW4.6 (3,156 ratings)
Format:Capsule Quantity: 60 Capsule(s) · 60 servings
Goals

Product analysis

64 out of 100

SAMe 200 mg offers a straightforward way to take SAMe for its role in normal metabolism, with clear labeling that makes comparisons easier.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality40

The SAMe form is clearly identified. Its name alone does not establish how well it is absorbed or a quality advantage.

Ingredient Transparency100

Both the SAMe amount and form are stated. That makes it easier to identify what you are buying and compare servings.

Value For Money40

The cost relative to the active amount offers modest value. Clear labeling helps with price comparisons, but does not establish that the serving will deliver a particular benefit.

Customer Satisfaction85

Customer feedback is very positive across several thousand ratings. The broad response supports an established picture of satisfaction, without proving liver benefits.

Product Focus72

The single-ingredient formula is linked to liver support through SAMe’s role in metabolism. Findings from a different regimen in people with liver disease do not establish routine toxin removal from this serving.

Format
Capsule
Container
60 Capsule(s)
Per serving
$0.30
Customer rating
4.6 · 3,156 ratings
Report analysis

Goals

Liver & Detox
Impact
High effect
B+ Ingredient FitF PathwaysA- EvidenceA+ Formulation Logic
SAMe · 200 mg
Study evidence
SAMe Supportive 30 studies

Ingredients

IngredientAmount per servingScore
SAMe (S-Adenosyl-L-Methionine Disulfate Tosylate)
200 mg 63
Gluten Free Adults 18–50 Vegan Dairy Free Vegetarian
Report overview
B Active Ingredient Quality & BioavailabilityC Dose, Safety & Label TransparencyD- Value
The serving provides 200 mg of SAMe at a low cost per 400 mg. Blister packaging is not documented. The active yield is not clearly separated from the salt weight.
How this ingredient is rated

Active Ingredient Quality & Bioavailability77

A stabilized SAMe salt is indicated, but its specific form is unclear. Protective blister packaging is not documented, so moisture protection is unclear.
Stabilized Salt Form
A stabilized SAMe salt is indicated, but its specific form is unclear.
Packaging Integrity
Protective blister packaging is not documented, so moisture protection is unclear.

Dose, Safety & Label Transparency60

A serving lists 200 mg of SAMe. The amount is not clearly distinguished as active SAMe versus salt weight.
Active Dosage Strength
A serving lists 200 mg of SAMe.
Net SAMe Yield Transparency
The amount is not clearly distinguished as active SAMe versus salt weight.

Value40

The cost per 400 mg of SAMe is low. Enteric coating or delayed release is not documented, leaving protection from stomach acid uncertain.
Price Per 400mg Active Dose
The cost per 400 mg of SAMe is low. Enteric coating or delayed release is not documented, leaving protection from stomach acid uncertain.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
    Noureddin M; Sander-Struckmeier S; Mato JM · World journal of hepatology · 2020
    Systematic review9 studies pooledLiver & Detox forSAMe
  2. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
    Zhang L; Liu XH; Qi HB; Li Z; Fu XD; Chen L; Shao Y · European review for medical and pharmacological sciences · 2016
    Randomized trial120 participantsLiver & Detox forSAMe
  3. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q · PloS one · 2015
    Meta-analysis705 participants11 studies pooledLiver & Detox forSAMe
  4. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
    Liu GY; Wang W; Jia WD; Xu GL; Ma JL; Ge YS; Yu JH; Sun QK; Meng FL · World journal of surgical oncology · 2014
    Non-randomized trial81 participantsLiver & Detox forSAMe
  5. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
    Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J · Journal of hepatology · 1999
    Randomized trial123 participantsLiver & Detox forSAMe